ONCOLYTICS ISSUED U.S. PATENT FOR PRODUCING REOVIRUS.Oncolytics Biotech Inc. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension : ONC (Open Network Computing) A family of networking products from Sun for implementing distributed computing in a multivendor environment. Includes TCP/IP and OSI protocols, NFS distributed file system, NIS naming service and TI-RPC remote procedure call library. , NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ONCY), Calgary, has been granted U.S. Patent 7,049,127 entitled "Method of Producing Infectious Reovirus reovirus Any of a small group of animal and plant viruses that appear spheroidal and contain a core of RNA. Among the best-known genera are Orthoreovirus, Orbivirus, Rotavirus, and Phytoreovirus. The first three infect animals; the last can destroy rice, corn, and other crops. ." The claims describe a method for producing and purifying mammalian reovirus. "Effective production methodologies are essential for the development of REOLYSIN(R)," said Dr. Matt Coffey, chief scientific officer of Oncolytics. "This patent adds continued protection for key pieces of our growing intellectual property estate." About Oncolytics Biotech Inc. Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase I/II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation. For more information, visit http://www.oncolyticsbiotech.com or call 403/670-7377. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion